Ventus Therapeutics, a clinical-stage biopharmaceutical company, announced a multi-year collaboration with Genentech, a member of the Roche Group, to discover and optimize novel small-molecule candidates for challenging targets in major disease areas using Ventus’ proprietary drug discovery platform, ReSOLVE. Under the terms of the agreement, Ventus will use ReSOLVE for virtual screening and lead identification of novel small molecules against multiple targets, and Genentech will conduct subs...